B. Riley Wealth Advisors Inc. Boosts Stake in Sanofi (NASDAQ:SNY)

B. Riley Wealth Advisors Inc. raised its stake in Sanofi (NASDAQ:SNY) by 32.4% during the first quarter, Holdings Channel.com reports. The institutional investor owned 20,925 shares of the company’s stock after purchasing an additional 5,117 shares during the quarter. B. Riley Wealth Advisors Inc.’s holdings in Sanofi were worth $1,122,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Cascade Investment Advisors Inc. grew its position in Sanofi by 4.7% during the first quarter. Cascade Investment Advisors Inc. now owns 34,359 shares of the company’s stock valued at $1,670,000 after acquiring an additional 1,535 shares during the last quarter. Vestal Point Capital LP bought a new position in shares of Sanofi during the fourth quarter valued at about $14,919,000. Dynamic Advisor Solutions LLC lifted its stake in shares of Sanofi by 39.2% in the 1st quarter. Dynamic Advisor Solutions LLC now owns 57,204 shares of the company’s stock valued at $2,780,000 after acquiring an additional 16,117 shares during the last quarter. Oxbow Advisors LLC bought a new stake in Sanofi in the fourth quarter valued at approximately $4,689,000. Finally, China Universal Asset Management Co. Ltd. grew its holdings in shares of Sanofi by 348.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 32,456 shares of the company’s stock worth $1,614,000 after purchasing an additional 25,213 shares during the last quarter. 10.04% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

SNY has been the topic of a number of analyst reports. StockNews.com upgraded shares of Sanofi from a “buy” rating to a “strong-buy” rating in a research report on Thursday. Argus lifted their price target on shares of Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a report on Friday, July 26th. Three analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Trading Down 1.0 %

SNY opened at $51.28 on Thursday. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. Sanofi has a 52 week low of $42.63 and a 52 week high of $55.72. The stock has a market cap of $129.88 billion, a PE ratio of 26.04, a PEG ratio of 1.50 and a beta of 0.59. The business has a 50 day moving average of $49.37 and a 200-day moving average of $48.68.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Thursday, July 25th. The company reported $0.93 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.05. The company had revenue of $10.75 billion during the quarter, compared to analysts’ expectations of $16.86 billion. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. Sanofi’s revenue was up 7.8% on a year-over-year basis. During the same period last year, the company posted $0.95 EPS. Equities research analysts predict that Sanofi will post 4.16 earnings per share for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.